Diabecare Grisi Diabetics
Dimethicone
Grisi Hnos, S.a De C.v
Human Otc Drug
NDC 68437-013Diabecare Grisi Diabetics also known as Dimethicone is a human otc drug labeled by 'Grisi Hnos, S.a De C.v'. National Drug Code (NDC) number for Diabecare Grisi Diabetics is 68437-013. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Diabecare Grisi Diabetics drug includes Dimethicone - 1.2 g/100mL . The currest status of Diabecare Grisi Diabetics drug is Active.
Drug Information:
| Drug NDC: | 68437-013 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Diabecare Grisi Diabetics |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Dimethicone |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Grisi Hnos, S.a De C.v |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lotion |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | DIMETHICONE - 1.2 g/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 08 Jul, 2019 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 08 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | M016 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | GRISI Hnos, S.A DE C.V
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 876980
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0037836085031
|
| UPC stands for Universal Product Code. |
| NUI: | N0000010282
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | 92RU3N3Y1O
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class PE: | Skin Barrier Activity [PE]
|
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. |
| Pharmacologic Class: | Skin Barrier Activity [PE]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 68437-013-12 | 350 mL in 1 BOTTLE, PLASTIC (68437-013-12) | 08 Jul, 2019 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose/utilidad skin protectant/protector de piel
Product Elements:
Diabecare grisi diabetics dimethicone niacinamide cetostearyl alcohol sorbitan monostearate shea butter isopropyl palmitate cetyl alcohol avocado oil peg-75 stearate glyceryl monostearate ceteth-20 steareth-20 yellow wax phenoxyethanol decylene glycol caprylyl glycol edetate sodium edetic acid butylated hydroxytoluene dimethicone dimethicone petrolatum glycerin water
Indications and Usage:
Uses/usos â temporarily protects and helps relieve chafed or cracked skin/protege temporalmente y ayuda a aliviar la piel irritada o agrietada â helps protect from the drying effects of wind and cold weather / ayuda a proteger de la resequedad causada por el viento y el clima frÃo
Warnings:
Warnings/precauciones â for external use only / sólo para uso externo do not use on/no usar en â animal bites / picaduras de animales â deep or puncture wounds / heridas profundas o punzantes â serious burns /quemaduras graves when using this product/cuando use este producto â avoid contact with eyes/evite el contacto con los ojos stop use and ask a doctor if / suspenda su uso y consulte a su médico si â condition worsens / la condición empeora â symptoms last more than 7 days or clear up and occur again within a few days/los sÃntomas persisten por más de 7 dÃas o mejoran y vuelven a aparecer a los pocos dÃas keep out of reach of children. manténgase fuera del alcance de los niños
Do Not Use:
Warnings/precauciones â for external use only / sólo para uso externo do not use on/no usar en â animal bites / picaduras de animales â deep or puncture wounds / heridas profundas o punzantes â serious burns /quemaduras graves when using this product/cuando use este producto â avoid contact with eyes/evite el contacto con los ojos stop use and ask a doctor if / suspenda su uso y consulte a su médico si â condition worsens / la condición empeora â symptoms last more than 7 days or clear up and occur again within a few days/los sÃntomas persisten por más de 7 dÃas o mejoran y vuelven a aparecer a los pocos dÃas keep out of reach of children. manténgase fuera del alcance de los niños
When Using:
When using this product/cuando use este producto â avoid contact with eyes/evite el contacto con los ojos
Dosage and Administration:
Directions/modo de uso â apply generously to affected area as needed/aplique generosamente sobre el area afectada según sea necesario
Stop Use:
Stop use and ask a doctor if / suspenda su uso y consulte a su médico si â condition worsens / la condición empeora â symptoms last more than 7 days or clear up and occur again within a few days/los sÃntomas persisten por más de 7 dÃas o mejoran y vuelven a aparecer a los pocos dÃas
Package Label Principal Display Panel:
Package label package label